Guanfacine
NDC 42291-325
Product Information
Guanfacine is a ANDA-approved product labeled by Avkare. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a orange product. This product entry covers the primary NDC 42291-325 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
OVAL (C48345)
12 MM
850
851
Code Structure Chart
Product Details
What is NDC 42291-325?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- GUANFACINE HYDROCHLORIDE (UNII: PML56A160O)
- GUANFACINE (UNII: 30OMY4G3MK) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- CROSPOVIDONE (UNII: 68401960MK)
- FUMARIC ACID (UNII: 88XHZ13131)
- GLYCERYL BEHENATE/EICOSADIOATE (UNII: 73CJJ317SR)
- HYDROXYPROPYL CELLULOSE (TYPE G) (UNII: VQ8ZWO78F6)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- POVIDONES (UNII: FZ989GH94E)
- FD&C YELLOW NO. 6 (UNII: H77VEI93A8)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 862006 - guanFACINE 1 MG 24HR Extended Release Oral Tablet
- RxCUI: 862006 - 24 HR guanfacine 1 MG Extended Release Oral Tablet
- RxCUI: 862006 - guanfacine 1 MG (as guanfacine hydrochloride 1.14 MG) 24 HR Extended Release Oral Tablet
- RxCUI: 862006 - guanfacine 1 MG (as guanfacine hydrochloride 1.15 MG) 24 HR Extended Release Oral Tablet
- RxCUI: 862013 - guanFACINE 2 MG 24HR Extended Release Oral Tablet
* Please review the full disclaimer at the bottom of this page.